<SEC-DOCUMENT>0001193125-22-185479.txt : 20220630
<SEC-HEADER>0001193125-22-185479.hdr.sgml : 20220630
<ACCEPTANCE-DATETIME>20220630060428
ACCESSION NUMBER:		0001193125-22-185479
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220630
DATE AS OF CHANGE:		20220630

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		221056416

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d375903d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of June, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia
Therapeutics Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9745; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
&#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> <B></B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kate Hill </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 30 June 2022 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g375903g45f49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30 June 2022
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA PROVIDES PROGRESS UPDATE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ON PAXALISIB AND EVT801 CLINICAL PROGRAMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 30</B><B></B><B>&nbsp;June 2022</B> &#150; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is
pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801, and on recent corporate financing activity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key
Points </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EVT801 phase I study protocol has cleared third dose level and is recruiting well. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">GBM AGILE pivotal study has opened in France, the fourth country to commence recruitment to the paxalisib arm.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase I study of paxalisib in combination with radiotherapy for treatment of brain metastases at Memorial Sloan
Kettering Cancer Center has been accepted for presentation at an upcoming academic conference in Q3 CY2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ATM financing facility has realized gross proceeds of US$ 2,956,036 for the period ending June 2022, at an
average price of $6.08 (approximately AU$ 0.88 per share). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia CEO, Dr James Garner, commented, &#147;Despite a challenging first
half equity market for biotech companies, Kazia has continued to make good progress. The GBM AGILE pivotal study is progressing well, and appears on track for data in 2H CY2023, as anticipated. We have been pleased in the first half to see new data
presented and milestones delivered from several projects, and we expect that pace to continue and increase during the second half.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EVT801 Phase
I Study </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The phase I study of EVT801 in patients with advanced cancer continues to recruit well. The drug has recently completed the third of a
potential eight dose levels and is anticipated to open recruitment to the fourth dose cohort in the near future. To date, the drug appears generally well-tolerated. Depending on how many dose cohorts are required to establish a maximum tolerated
dose (MTD), interim data from the study is anticipated in 2H CY2022 or 1H CY2023. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GBM AGILE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More than forty sites are currently open to the paxalisib arm of GBM AGILE. The first site to commence recruitment to the paxalisib arm in France opened in
June 2022, making France the fourth country to join the study, alongside the United States, Canada, and Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2022, the Global
Coalition for Adaptive Research (GCAR), the sponsor of GBM AGILE, stated that over a thousand patients had been screened to the study, with enrolment rates approximating 0.75 to 1.00 patients per site per month, which is around four times higher
than would generally be expected in a clinical study of glioblastoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia continues to work closely with GCAR and Simcere Pharmaceutical to open the
study in China. Public health measures in some Chinese cities relating to the ongoing COVID pandemic have had a modest impact on operational activities, but it is currently anticipated that the study will open in China during 3Q CY2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Paxalisib in Brain Metastases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2022, the company
announced that a multi-drug, genomically-guided study in brain metastases run by the Alliance for Clinical Trials in Oncology had seen the paxalisib arm graduate to an expansion cohort in patients with breast cancer brain metastases, having seen
positive efficacy signals in the initial exploratory cohort. Paxalisib continues to recruit to the exploratory cohort in two other patient subgroups. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim data from a phase I study of paxalisib in combination with radiotherapy for patients with brain metastases run by Memorial Sloan Kettering Cancer
Center has been accepted for an oral presentation at an upcoming international conference in Q3 CY2022. Kazia looks forward to sharing data from this presentation as soon as it is available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2022, Kazia established a NASDAQ-based <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> financing facility with Oppenheimer and Company. For the period ending June&nbsp;30, 2022, the company has issued 486,281 American Depository Shares (ADSs) under
this facility, at an average price of $6.08, for total gross proceeds of US$ 2,956,036 (approximately AU$ 4,256,691). Of note, these shares have been issued at no discount, with no warrant coverage, and with transaction fees approximately half of
those associated with traditional financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For More Information, Please Contact:- </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>In the United States:</U></I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joe Green</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Edison Investor Relations</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jgreen@edisongroup.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Phone: +1 <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">646-653-7030</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>In Australia:</U></I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jane Lowe</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IR Department</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jane.lowe@irdepartment.com.au</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Phone: +61 411 117
774</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common
and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Seven additional studies are active in various forms of
brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease
Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for AT/RT in June 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule
inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study
commenced recruitment in November 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U> or follow us on Twitter @KaziaTx. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain
forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148; &#147;intend,&#148; &#147;potential,&#148; &#147;prospective,&#148; or other similar words. Any statement describing Kazia&#146;s
future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements. Such statements are based on Kazia&#146;s expectations and projections about
future events and future trends affecting our business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and
uncertainties associated with clinical trials and product development and the impact of global economic conditions. These and other risks and uncertainties, are described more fully in Kazia&#146;s Annual Report, filed on form <FONT
STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings to SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as
required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. Actual results could differ materially from those discussed in this announcement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g375903g45f49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g375903g45f49.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( (X#- ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\)P*3<*24XC;Z5^:_Q<_X.2O
M_P (OC%XR\&W'PQ\:7UUX+\0:CX>GNH;VT2*YELKJ6V>1 S;@K-$6 /.".^:
MUI49U':"N9U*T*:O-V/TIW"C<*_+?_B*,\!?]$G\=_\ @PLO_BZ/^(HOP#_T
M2GQY_P"#"Q_^+K7ZCB/Y&<_UZA_.C]2-PHW"ORW_ .(HOP#_ -$I\>?^!]C_
M /%T?\11G@+_ *)/X[_\&%E_\71]1Q'\C#Z]0_G1^I&X4;A7Y;_\11G@(_\
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M1G@'_HE'CS_P86/_ ,71]1Q'\C#Z]0_G7XGZD;A1N%?EO_Q%%^ ?^B4^//\
MP/L?_BZ/^(HSP"/^:4^//_!A8_\ Q='U'$?R,/KU#^='ZD;A1N%?EO\ \11G
M@+_HD_CO_P &%E_\71_Q%%^ ?^B4^//_  86/_Q='U'$?R,/KU#^=?B?J1N%
M&X5^6_\ Q%%^ ?\ HE/CS_P86/\ \71_Q%&> O\ HD_CO_P867_Q='U'$?R,
M/KU#^=?B?J1N%&X5^6__ !%&> 3_ ,TH\>?^#"Q_^+H_XBB_ /\ T2GQY_X'
MV/\ \71]1Q'\C']>H?SH_4C<*-PK\M_^(HSP$/\ FE'CS_P86/\ \71_Q%&>
M O\ HD_CO_P867_Q='U'$?R,7UZA_.OQ/U(W"C<*_+?_ (BB_ /_ $2GQY_X
M'V/_ ,71_P 11?@'_HE/CS_P86/_ ,73^HXC^1C^O4/YU^)^I&X4;A7Y;_\
M$49X"_Z)/X[_ /!A9?\ Q='_ !%&> 3_ ,TH\>?^#"Q_^+I?4<1_(Q?7J'\Z
M_$_4C<*-PK\M_P#B*+\ _P#1*?'G_@?8_P#Q='_$49X"_P"B3^.__!A9?_%T
M?4<1_(P^O4/YU^)^I&X4;A7Y;_\ $49X"_Z)/X[_ /!A9?\ Q='_ !%%^ ?^
MB4^//_ ^Q_\ BZ/J.(_D8?7J'\Z_$_4C<*-PK\M_^(HOP#_T2GQY_P"#"Q_^
M+H_XBC/ 7_1)_'?_ (,++_XNCZCB/Y&'UZA_.OQ/U(W"C<*_+?\ XBB_ /\
MT2GQY_X,+'_XNC_B*+\ _P#1*?'G_@?8_P#Q='U'$?R,/KU#^='ZD;A1N%?E
MO_Q%&> O^B3^._\ P867_P 71_Q%&> O^B4>._\ P86/_P 71]1Q'\C#Z]0_
MG7XGZD;A1N%?EO\ \11?@'_HE/CS_P #['_XNC_B*,\!#_FE'CS_ ,&%C_\
M%T?4<1_(P^O4/YT?J1N%&X5^6_\ Q%&> O\ HD_CO_P867_Q='_$47X!_P"B
M4^//_!A8_P#Q='U'$?R,/KU#^=?B?J1N%&X5^6__ !%%^ ?^B4^//_ ^Q_\
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MC/ 7_1*/'G_@PL?_ (NCZCB/Y&'UZA_.OQ/U(W"C<*_+?_B*+\ _]$I\>?\
M@?8__%T?\11G@$?\TH\>?^#"Q_\ BZ/J.(_D8?7J'\Z/U(W"C<*_+?\ XBC/
M 7_1)_'?_@PLO_BZ/^(HOP#_ -$I\>?^#"Q_^+H^HXC^1A]>H?SK\3]2-PHW
M"ORW_P"(HOP#_P!$I\>?^!]C_P#%T?\ $49X"_Z)/X[_ /!A9?\ Q='U'$?R
M,/KU#^=?B?J1N%&X5^6__$49X!/_ #2CQY_X,+'_ .+H_P"(HOP#_P!$I\>?
M^!]C_P#%T?4<1_(Q_7J'\Z/U(W"C<*_+?_B*,\ _]$H\>?\ @PL?_BZ/^(HS
MP%_T2?QW_P"#"R_^+H^HXC^1B^O4/YU^)^I&X4;A7Y;_ /$47X!_Z)3X\_\
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M\_\ !A8__%T?\11?@'_HE/CS_P #['_XNCZCB/Y&/Z]0_G1^I&X4;A7Y;_\
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M-'_?- !C_=HQ_NT?]\T?]\T &/\ =HQ_NT?]\T?]\T &/]VC'^[1_P!\T?\
M?- !C_=HQ_NT?]\T?]\T &/]VC'^[1_WS1_WS0 8_P!VC'^[1_WS1_WS0 8_
MW:,?[M'_ 'S1_P!\T &/]VC'^[1_WS1_WS0 8_W:,?[M'_?-'_?- !C_ ':,
M?[M'_?-'_?- !C_=HQ_NT?\ ?-'_ 'S0 8_W:,?[M'_?-'_?- !C_=HQ_NT?
M]\T?]\T &/\ =HQ_NT?]\T?]\T &/]VC'^[1_P!\T?\ ?- !C_=HQ_NT?]\T
M?]\T &/]VC'^[1_WS1_WS0 8_P!VC'^[1_WS1_WS0 8_W:,?[M'_ 'S1_P!\
MT &/]VC'^[1_WS1_WS0 8_W:,?[M'_?-'_?- !C_ ':,?[M'_?-'_?- !C_=
MHQ_NT?\ ?-'_ 'S0 8_W:,?[M'_?-'_?- !C_=HQ_NT?]\T?]\T &/\ =HQ_
MNT?]\T?]\T &/]VC'^[1_P!\T?\ ?- !C_=HQ_NT?]\T?]\T &/]VC'^[1_W
MS1_WS0 8_P!VC'^[1_WS1_WS0 ZV'^D1_=^]VK^E3_@CU_RBN_9[_P"Q!TC_
M -)8Z_FKM_\ CXC^[]ZOZ5/^"/7_ "BN_9[_ .Q!TC_TECKQLZ_AQ]?T1ZN3
M_'+T_5GTA1117SA[XV3_ %;?2OY8?VSSC]M[X[?=_P"2F>*.O_89O*_J>D_U
M;?2OY8?VSSC]M[X[<_\ -3/%'_IYO*]C)?XK]/U/'SC^''U/.=W^[1N_W:-W
M^T/RHW?[0_*OI#PPW?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\
M=HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0
M_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]
MVC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#
M\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W
M:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\
M=HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0
M_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]
MVC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#
M\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W
M:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@!UL?](C^[][M7]*G_  1Z_P"45W[/?_8@
MZ1_Z2QU_-7;G-Q'R/O5_2I_P1Z_Y17?L]_\ 8@Z1_P"DL=>-G7\./K^B/6RC
MXY>GZL^D****^</>&R?ZMOI7\L/[9YQ^V]\=N?\ FIGBCM_U&;NOZGI/]6WT
MK^6']L\X_;>^.W/_ #4SQ1V_ZC-Y7LY+_%?I^IX^<?PX^IYSN_VOTHW?[7Z4
M;O\ :_2C=_M?I7T9X8;O]K]*-W^U^E&[_:_2C=_M?I0 ;O\ :_2C=_M?I06]
M_P!*]NT[]A_4-0_X)XZA^T"OB73_ "K#4VB_X1EK<&ZETX:A_9C:CYBR;MBW
M@*&(1Y*JS;^1B)5(QMS/?0J,7+X?4\1W?[7Z4;O]K]*]R^*?[%EI\&OV:M$\
M;ZM\1]"7Q5KWA#2O'FG^$'LGBN-2TF]E,:+973LL5W?1 ;Y;95QM/$FTAJT_
MVC/^">M_\ /!"^(H?%2^)M)\4:WI.C_#633]+8R_$>*^LH[QKNWA\TR1Q0K<
M16^%$IDG94#*<9S6*I-V3-/J]1=#YZW?[7Z4;N>M>H?LY_LJ:]^TSI'Q(_X1
M\S2>(OA_9:;-;:.MH9)-9NK[41816V[<OV?#X=G<-M (*CDKW?PT_8F\#_$3
M]KC5/@Y;_&2:;7H=;A\/:+=Z=X(N=2A\077E.U\%\NX BAM&20&9CB1$,J;5
MXISQ$(WOTW%&A.232WV/G3=S][]*-W^U^E>__L^_L&_\-*ZG\7E\.^.-/DT_
MX=S7-GX9NDTYYQ\0[I(=1N;>WM,2 1F6TL#,&;?@2J<$Y)\;^&G@L?$W1/&5
MY#??91X2\+-XF4&$O]L OK"U\GJ-G_'[OW8/,6W&&R"->#Z[?KL'L)JUUO\
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M?I1N_P!K]*-W^U^E&[_:_2@ W?[7Z4;O]K]*-W^U^E&[_:_2@ W?[7Z4;O\
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M1#ACDAB-PKTJ.7WA"M5DHP<K/NO.Q\WBL_:KU<%A*;G5C#FC?2+?:YX+XA\
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M"VT'@MC )&2,C/0?\,]_$3_HG_CS_P )V]_^-5,IQ3LV-1;V.1W?[7Z4;O\
M:_2NDUWX,>-?"^D3ZAJG@WQ?I>GVH!GN[S1+JWMX 6"@O(\851N(&21R:YE)
M-Z*V?O ,..Q&1^AH4DU=#Y6G9CMW^U^E&[_:_2M3PGX%\0>/KBYBT'0=;UZ2
MS1);A-,L);QK=7+!&=8E8H&*. 6 !V'&:JZYH>H>%]7N-/U2QOM+U"U8)/:W
MEN\$\!*AP'1P&4E65@" 2&!HYES<O4G6W-T*N[_:_2C=_M?I1N_VOTH+>_Z5
M0!N_VOTHW?[7Z5<O_#FJ:5X=TO6+K3-2M=(UUK@:9?36KQVVH_9W6.?R9& 6
M3RV9%?83L+@-@\"F'SW_ $J5)/5!L[,-W^U^E&[_ &OTHW?[7Z4;O]K]*H W
M?[7Z4;O]K]*-W^U^E&[_ &OTH =;'-Q'_O5_2I_P1Z_Y17?L]_\ 8@Z1_P"D
ML=?S5VY_TB/_ 'O2OZ5/^"/7_**[]GO_ +$'2/\ TECKQLZ_AQ]?T1ZN3_'+
MT_5GTA1117SA[XV3_5M]*_EA_;/_ .3WOCMU_P"2F>*.@_ZC-Y7]3TG^K;Z5
M_+#^V?\ \GO?';[W_)3/%'_IYO*]C)?XK]/U/'SC^''U/.<^[?E1GW;\J/\
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MY49]V_*C_OJC_OJ@ S[M^5&?=ORH_P"^J/\ OJ@ S[M^5&?=ORH_[ZH_[ZH
M,^[?E1GW;\J/^^J/^^J #/NWY49]V_*C_OJC_OJ@ S[M^5&?=ORH_P"^J/\
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M;M2\;LNK^(U1OFM]*A?]W$3U7[1<*J\9W1PSCCJ/QI<_,WS-U)SLVY_#H*]
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M^*O!G@%=8C\3>)=0\'1>'[W7KFXFU"YC@L8M/749;=HFM-0FNKBXE2"'9&\
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MV?UHQ_LK1C_96@ Q_L_K1C_9_6C'^RM&/]E: #'^S^M&/]G]:,?[*T8_V5H
M,?[/ZT8_V?UHQ_LK1C_96@ Q_L_K1C_9_6C'^RM&/]E: #'^S^M&/]G]:,?[
M*T8_V5H ,?[/ZT8_V?UHQ_LK1C_96@ Q_L_K1C_9_6C'^RM&/]E: #'^S^M&
M/]G]:,?[*T8_V5H 0IGM5WP]X@U'PAK,&I:3?7FEZA:G,-U:RF*:,^SCG&,@
MCH0>0:IX_P!E:,?[*U2DT[H4HJ2Y9:HT-?\ %NK^*_$?]L:GJ>H:AJP*L+RX
MN&DF!4Y4AB<C!Y&,8J;QCX\U[XAWT%UKVL:IK5Q:HT<3WMT\QC4G) W$XR>3
MCJ>3FLG'^RM&/]E:/:2LU=Z[^9G["G=2Y5>.VBT].PFS!Z4H7 ^[1C_96C'^
MRM2:AC_9_6C'^S^M&/\ 96C'^RM !C_9_6C'^S^M&/\ 96C'^RM !C_9_6C'
M^S^M&/\ 96C'^RM !C_9_6C'^S^M&/\ 96C'^RM !C_9_6C'^S^M&/\ 96C'
M^RM !C_9_6C'^S^M&/\ 96C'^RM !C_9_6C'^S^M&/\ 96C'^RM !C_9_6C'
M^S^M&/\ 96C'^RM !C_9_6C'^S^M&/\ 96C'^RM !C_9_6C'^S^M&/\ 96C'
M^RM !C_9_6C'^S^M&/\ 96C'^RM !C_9_6C'^S^M&/\ 96C'^RM #K<8N(^/
MXJ_I4_X(]?\ **[]GO\ [$'2/_26.OYJ[8?Z1'POWNU?TJ?\$>O^45W[/?\
MV(.D?^DL=>-G7\./K^B/6RCXY>GZL^D****^</>&SAC"VW[V.*_'/X]_\&W?
MQ/\ BU^T)\1/&%C\0O =K8^,_%FK^(;:WN+>[::WBO+Z>Y2-RJXW*LH4XR,@
M\D5^QQ&10%Q6]#$5*+YJ;,:V'A55IH_$?_B%_P#BS_T4GX<_^ M[_P#$T?\
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M]_P#^S*';\6?B/\ \0P'Q8_Z*5\.?_ :]_\ B:/^(8#XL?\ 12OAS_X#7O\
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M]_P#^S:';\6?B.?^#8#XL9_Y*5\.?_ :]_\ B:/^(8#XL?\ 12OAS_X#7O\
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M/?\  /[-H=OQ9^(Y_P"#7_XLX_Y*3\.?_ 6]_P#B:/\ B& ^+'_12OAS_P"
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8@8KGKXNK6_B,Z*.%ITM8(****YSH/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
